{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T08:04:33Z","timestamp":1794989073415,"version":"4.9.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cerebrospinal fluid (CSF) total tau (t-tau) is considered a biomarker of neuronal degeneration alongside brain atrophy and fluid neurofilament light chain protein (NfL) in biomarker models of Alzheimer\u2019s disease (AD). However, previous studies show that CSF t-tau correlates strongly with synaptic dysfunction\/degeneration biomarkers like neurogranin (Ng) and synaptosomal-associated protein 25 (SNAP25). Here, we compare the association between CSF t-tau and synaptic degeneration and axonal\/neuronal degeneration biomarkers in cognitively unimpaired and impaired groups from two independent cohorts. We observe a stronger correlation between CSF t-tau and synaptic biomarkers than neurodegeneration biomarkers in both groups. Synaptic biomarkers explain a greater proportion of variance in CSF t-tau levels compared to neurodegeneration biomarkers. Notably, CSF t-tau levels are elevated in individuals with abnormalities only in synaptic biomarkers, but not in individuals with abnormalities only in neurodegeneration biomarkers. Our findings suggest that CSF t-tau is a closer proxy for synaptic degeneration than for axonal\/neuronal degeneration.<\/jats:p>","DOI":"10.1038\/s41467-025-63545-5","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T09:27:51Z","timestamp":1756459671000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["CSF total tau as a proxy of synaptic degeneration"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2338-4495","authenticated-orcid":false,"given":"Carolina","family":"Soares","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruna","family":"Bellaver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2134-9829","authenticated-orcid":false,"given":"Pamela C. L.","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilherme","family":"Povala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7378-3830","authenticated-orcid":false,"given":"Cristiano","family":"Schaffer Aguzzoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2183-1551","authenticated-orcid":false,"given":"Jo\u00e3o Pedro","family":"Ferrari-Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussein","family":"Zalzale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Firoza Z.","family":"Lussier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francieli","family":"Rohden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilherme","family":"Bauer-Negrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4890-8451","authenticated-orcid":false,"given":"Douglas","family":"Teixeira Leffa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9a Lessa","family":"Benedet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Langhough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8856-1352","authenticated-orcid":false,"given":"Tobey J.","family":"Betthauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9653-559X","authenticated-orcid":false,"given":"Bradley T.","family":"Christian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael E.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"L. Tudorascu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9116-1376","authenticated-orcid":false,"given":"Pedro","family":"Rosa-Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1422-4358","authenticated-orcid":false,"given":"Thomas K.","family":"Karikari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3930-4354","authenticated-orcid":false,"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1890-4193","authenticated-orcid":false,"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5349-0053","authenticated-orcid":false,"given":"Eduardo R.","family":"Zimmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8501-545X","authenticated-orcid":false,"given":"Sterling C.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9057-8014","authenticated-orcid":false,"given":"Tharick A.","family":"Pascoal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,29]]},"reference":[{"key":"63545_CR1","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/0022-510X(87)90057-8","volume":"78","author":"CA Davies","year":"1987","unstructured":"Davies, C. A., Mann, D. M. A., Sumpter, P. Q. & Yates, P. O. A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer\u2019s disease. J. Neurol. Sci. 78, 151\u2013164 (1987).","journal-title":"J. Neurol. Sci."},{"key":"63545_CR2","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1002\/ana.410300410","volume":"30","author":"RD Terry","year":"1991","unstructured":"Terry, R. D. et al. Physical basis of cognitive alterations in Alzheimer\u2019s disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 30, 572\u2013580 (1991).","journal-title":"Ann. Neurol."},{"key":"63545_CR3","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1016\/j.celrep.2017.03.013","volume":"18","author":"JS Jackson","year":"2017","unstructured":"Jackson, J. S. et al. Altered synapse stability in the early stages of tauopathy. Cell Rep. 18, 3063\u20133068 (2017).","journal-title":"Cell Rep."},{"key":"63545_CR4","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.neuron.2010.11.030","volume":"68","author":"BR Hoover","year":"2010","unstructured":"Hoover, B. R. et al. Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron 68, 1067\u20131081 (2010).","journal-title":"Neuron"},{"key":"63545_CR5","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack","year":"2018","unstructured":"Jack, C. R. et al. NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 14, 535\u2013562 (2018).","journal-title":"Alzheimers Dement."},{"key":"63545_CR6","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1073\/pnas.72.5.1858","volume":"72","author":"MD Weingarten","year":"1975","unstructured":"Weingarten, M. D., Lockwood, A. H., Hwo, S. Y. & Kirschner, M. W. A protein factor essential for microtubule assembly. PNAS 72, 1858\u20131862 (1975).","journal-title":"PNAS"},{"key":"63545_CR7","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1084\/jem.20131685","volume":"211","author":"K Yamada","year":"2014","unstructured":"Yamada, K. et al. Neuronal activity regulates extracellular tau in vivo. J. Exp. Med. 211, 387\u2013393 (2014).","journal-title":"J. Exp. Med."},{"key":"63545_CR8","doi-asserted-by":"publisher","first-page":"6084","DOI":"10.1523\/JNEUROSCI.4261-13.2014","volume":"34","author":"ML Frandemiche","year":"2014","unstructured":"Frandemiche, M. L. et al. Activity-dependent tau protein translocation to excitatory synapse is disrupted by exposure to amyloid-beta oligomers. J. Neurosci. 34, 6084\u20136097 (2014).","journal-title":"J. Neurosci."},{"key":"63545_CR9","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.neuint.2011.12.013","volume":"60","author":"Q Chen","year":"2012","unstructured":"Chen, Q. et al. Tau protein is involved in morphological plasticity in hippocampal neurons in response to BDNF. Neurochem. Int. 60, 233\u2013242 (2012).","journal-title":"Neurochem. Int."},{"key":"63545_CR10","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1001\/jamaneurol.2023.3530","volume":"80","author":"RN Taddei","year":"2023","unstructured":"Taddei, R. N. et al. Tau oligomer\u2013containing synapse elimination by microglia and astrocytes in Alzheimer disease. JAMA Neurol. 80, 1209 (2023).","journal-title":"JAMA Neurol."},{"key":"63545_CR11","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1016\/j.neuron.2023.04.020","volume":"111","author":"M Colom-Cadena","year":"2023","unstructured":"Colom-Cadena, M. et al. Synaptic oligomeric tau in Alzheimer\u2019s disease \u2014 a potential culprit in the spread of tau pathology through the brain. Neuron 111, 2170\u20132183.e6 (2023).","journal-title":"Neuron"},{"key":"63545_CR12","doi-asserted-by":"publisher","first-page":"15295","DOI":"10.1038\/ncomms15295","volume":"8","author":"L Zhou","year":"2017","unstructured":"Zhou, L. et al. Tau association with synaptic vesicles causes presynaptic dysfunction. Nat. Commun. 8, 15295 (2017).","journal-title":"Nat. Commun."},{"key":"63545_CR13","doi-asserted-by":"publisher","first-page":"199","DOI":"10.3233\/JAD-2000-23-402","volume":"2","author":"C Hesse","year":"2000","unstructured":"Hesse, C. et al. Cerebrospinal fluid markers for Alzheimer\u2019s disease evaluated after acute ischemic stroke. J. Alzheimers Dis. 2, 199\u2013206 (2000).","journal-title":"J. Alzheimers Dis."},{"key":"63545_CR14","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/BF02815140","volume":"26","author":"K Blennow","year":"1995","unstructured":"Blennow, K. et al. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol. Chem. Neuropathol. 26, 231\u2013245 (1995).","journal-title":"Mol. Chem. Neuropathol."},{"key":"63545_CR15","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.15252\/emmm.201606540","volume":"8","author":"N Mattsson","year":"2016","unstructured":"Mattsson, N. et al. Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer\u2019s disease. EMBO Mol. Med. 8, 1184\u20131196 (2016).","journal-title":"EMBO Mol. Med."},{"key":"63545_CR16","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/j.jalz.2019.07.009","volume":"15","author":"MM Mielke","year":"2019","unstructured":"Mielke, M. M. et al. Comparison of variables associated with cerebrospinal fluid neurofilament, total-tau, and neurogranin. Alzheimers Dement. 15, 1437\u20131447 (2019).","journal-title":"Alzheimers Dement."},{"key":"63545_CR17","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1007\/s00259-018-4242-6","volume":"46","author":"A Leuzy","year":"2019","unstructured":"Leuzy, A. et al. Longitudinal tau and metabolic PET imaging in relation to novel CSF tau measures in Alzheimer\u2019s disease. Eur. J. Nucl. Med. Mol. Imaging 46, 1152\u20131163 (2019).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"63545_CR18","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1001\/archgenpsychiatry.2011.155","volume":"69","author":"P Buchhave","year":"2012","unstructured":"Buchhave, P. et al. Cerebrospinal fluid levels of amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch. Gen. Psychiatry 69, 98\u2013106 (2012).","journal-title":"Arch. Gen. Psychiatry"},{"key":"63545_CR19","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1212\/WNL.52.8.1555","volume":"52","author":"F Hulstaert","year":"1999","unstructured":"Hulstaert, F. et al. Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF. Neurology 52, 1555\u20131562 (1999).","journal-title":"Neurology"},{"key":"63545_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-20324-2","volume":"12","author":"Q Qiang","year":"2022","unstructured":"Qiang, Q., Skudder-Hill, L., Toyota, T., Wei, W. & Adachi, H. CSF GAP-43 as a biomarker of synaptic dysfunction is associated with tau pathology in Alzheimer\u2019s disease. Sci. Rep. 12, 17392 (2022).","journal-title":"Sci. Rep."},{"key":"63545_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13195-018-0407-6","volume":"10","author":"H Zhang","year":"2018","unstructured":"Zhang, H. et al. Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer\u2019s disease. Alzheimers Res. Ther. 10, 1\u201311 (2018).","journal-title":"Alzheimers Res. Ther."},{"key":"63545_CR22","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S1474-4422(13)70194-7","volume":"12","author":"SJB Vos","year":"2013","unstructured":"Vos, S. J. B. et al. Preclinical Alzheimer\u2019s disease and its outcome: a longitudinal cohort study. Lancet Neurol. 12, 957\u2013965 (2013).","journal-title":"Lancet Neurol."},{"key":"63545_CR23","doi-asserted-by":"publisher","first-page":"e953","DOI":"10.1212\/WNL.0000000000010131","volume":"95","author":"M Tible","year":"2020","unstructured":"Tible, M. et al. Dissection of synaptic pathways through the CSF biomarkers for predicting Alzheimer disease. Neurology 95, e953\u2013e961 (2020).","journal-title":"Neurology"},{"key":"63545_CR24","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.trci.2019.11.002","volume":"5","author":"D Galasko","year":"2019","unstructured":"Galasko, D. et al. Synaptic biomarkers in CSF aid in diagnosis, correlate with cognition and predict progression in MCI and Alzheimer\u2019s disease. Alzheimers Dement. Transl. Res. Clin. Interv. 5, 871\u2013882 (2019).","journal-title":"Alzheimers Dement. Transl. Res. Clin. Interv."},{"key":"63545_CR25","doi-asserted-by":"publisher","first-page":"E2065","DOI":"10.1212\/WNL.0000000000012853","volume":"97","author":"M Mil\u00e0-Alom\u00e0","year":"2021","unstructured":"Mil\u00e0-Alom\u00e0, M. et al. CSF synaptic biomarkers in the preclinical stage of Alzheimer disease and their association with MRI and PET a cross-sectional study. Neurology 97, E2065\u2013E2078 (2021).","journal-title":"Neurology"},{"key":"63545_CR26","doi-asserted-by":"publisher","first-page":"9365","DOI":"10.18632\/aging.103211","volume":"12","author":"M Xue","year":"2020","unstructured":"Xue, M. et al. Association of cerebrospinal fluid neurogranin levels with cognition and neurodegeneration in Alzheimer\u2019s disease. Aging 12, 9365\u20139379 (2020).","journal-title":"Aging"},{"key":"63545_CR27","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.neurobiolaging.2022.04.010","volume":"116","author":"D Vidal-Pi\u00f1eiro","year":"2022","unstructured":"Vidal-Pi\u00f1eiro, D. et al. Relationship between cerebrospinal fluid neurodegeneration biomarkers and temporal brain atrophy in cognitively healthy older adults. Neurobiol. Aging 116, 80\u201391 (2022).","journal-title":"Neurobiol. Aging"},{"key":"63545_CR28","doi-asserted-by":"publisher","first-page":"eadg4122","DOI":"10.1126\/scitranslmed.adg4122","volume":"15","author":"R Haque","year":"2023","unstructured":"Haque, R. et al. A protein panel in cerebrospinal fluid for diagnostic and predictive assessment of Alzheimer\u2019s disease. Sci. Transl. Med. 15, eadg4122 (2023).","journal-title":"Sci. Transl. Med."},{"key":"63545_CR29","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1002\/alz.12239","volume":"17","author":"MM Mielke","year":"2021","unstructured":"Mielke, M. M. et al. Comparison of CSF neurofilament light chain, neurogranin, and tau to MRI markers. Alzheimers Dement. 17, 801\u2013812 (2021).","journal-title":"Alzheimers Dement."},{"key":"63545_CR30","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.neurobiolaging.2017.06.002","volume":"58","author":"JB Pereira","year":"2017","unstructured":"Pereira, J. B., Westman, E. & Hansson, O. Association between cerebrospinal fluid and plasma neurodegeneration biomarkers with brain atrophy in Alzheimer\u2019s disease. Neurobiol. Aging 58, 14\u201329 (2017).","journal-title":"Neurobiol. Aging"},{"key":"63545_CR31","doi-asserted-by":"publisher","first-page":"e1315","DOI":"10.1212\/WNL.0000000000200035","volume":"98","author":"JL Ebenau","year":"2022","unstructured":"Ebenau, J. L. et al. Association of CSF, plasma, and imaging markers of neurodegeneration with clinical progression in people with subjective cognitive decline. Neurology 98, e1315\u2013e1326 (2022).","journal-title":"Neurology"},{"key":"63545_CR32","first-page":"e12005","volume":"12","author":"K Dhiman","year":"2020","unstructured":"Dhiman, K. et al. Cerebrospinal fluid neurofilament light concentration predicts brain atrophy and cognition in Alzheimer\u2019s disease. Alzheimers Dement. Diagn. Assess. Dis. Monit. 12, e12005 (2020).","journal-title":"Alzheimers Dement. Diagn. Assess. Dis. Monit."},{"key":"63545_CR33","first-page":"346","volume":"10","author":"I Ill\u00e1n-Gala","year":"2018","unstructured":"Ill\u00e1n-Gala, I. et al. Challenges associated with biomarker-based classification systems for Alzheimer\u2019s disease. Alzheimers Dement. Diagn. Assess. Dis. Monit. 10, 346\u2013357 (2018).","journal-title":"Alzheimers Dement. Diagn. Assess. Dis. Monit."},{"key":"63545_CR34","doi-asserted-by":"publisher","first-page":"S281","DOI":"10.3233\/JAD-179910","volume":"64","author":"L Parnetti","year":"2018","unstructured":"Parnetti, L. & Eusebi, P. Cerebrospinal fluid biomarkers in Alzheimer\u2019s disease: an invaluable tool for clinical diagnosis and trial enrichment. J. Alzheimer\u2019s Dis. 64, S281\u2013S287 (2018).","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"63545_CR35","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/BF00308809","volume":"82","author":"H Braak","year":"1991","unstructured":"Braak, H. & Braak, E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82, 239\u2013259 (1991).","journal-title":"Acta Neuropathol."},{"key":"63545_CR36","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1016\/j.neurobiolaging.2008.01.010","volume":"30","author":"J Barnes","year":"2009","unstructured":"Barnes, J. et al. A meta-analysis of hippocampal atrophy rates in Alzheimer\u2019s disease. Neurobiol. Aging 30, 1711\u20131723 (2009).","journal-title":"Neurobiol. Aging"},{"key":"63545_CR37","doi-asserted-by":"publisher","first-page":"32040","DOI":"10.1074\/jbc.M112.401240","volume":"287","author":"S Mondrag\u00f3n-Rodr\u00edguez","year":"2012","unstructured":"Mondrag\u00f3n-Rodr\u00edguez, S. et al. Interaction of endogenous tau protein with synaptic proteins is regulated by N-methyl-d-aspartate receptor-dependent tau phosphorylation. J. Biol. Chem. 287, 32040\u201332053 (2012).","journal-title":"J. Biol. Chem."},{"key":"63545_CR38","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s00401-009-0536-x","volume":"118","author":"T Arendt","year":"2009","unstructured":"Arendt, T. Synaptic degeneration in Alzheimer\u2019s disease. Acta Neuropathol. 118, 167\u2013179 (2009).","journal-title":"Acta Neuropathol."},{"key":"63545_CR39","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1002\/alz.12890","volume":"19","author":"G Lan","year":"2023","unstructured":"Lan, G., Li, A., Liu, Z., Ma, S. & Guo, T. Presynaptic membrane protein dysfunction occurs prior to neurodegeneration and predicts faster cognitive decline. Alzheimers Dement. 19, 2408\u20132419 (2023).","journal-title":"Alzheimers Dement."},{"key":"63545_CR40","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1002\/alz.12097","volume":"16","author":"AP Mecca","year":"2020","unstructured":"Mecca, A. P. et al. In vivo measurement of widespread synaptic loss in Alzheimer\u2019s disease with SV2A PET. Alzheimer\u2019s Dement. 16, 974\u2013982 (2020).","journal-title":"Alzheimer\u2019s Dement."},{"key":"63545_CR41","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1093\/brain\/awm136","volume":"130","author":"S Engelborghs","year":"2007","unstructured":"Engelborghs, S. et al. No association of CSF biomarkers with APOE\u03b54, plaque and tangle burden in definite Alzheimer\u2019s disease. Brain 130, 2320\u20132326 (2007).","journal-title":"Brain"},{"key":"63545_CR42","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1126\/science.1566067","volume":"256","author":"JA Hardy","year":"1992","unstructured":"Hardy, J. A. & Higgins, G. A. Alzheimer\u2019s disease: the amyloid cascade hypothesis. Science 256, 184\u2013185 (1992).","journal-title":"Science"},{"key":"63545_CR43","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/j.1365-2796.2004.01388.x","volume":"256","author":"RC Petersen","year":"2004","unstructured":"Petersen, R. C. Mild cognitive impairment as a diagnostic entity. J. Intern. Med. 256, 183\u2013194 (2004).","journal-title":"J. Intern. Med."},{"key":"63545_CR44","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/ana.21610","volume":"65","author":"LM Shaw","year":"2009","unstructured":"Shaw, L. M. et al. Cerebrospinal fluid biomarker signature in Alzheimer\u2019s disease neuroimaging initiative subjects. Ann. Neurol. 65, 403\u2013413 (2009).","journal-title":"Ann. Neurol."},{"key":"63545_CR45","first-page":"130","volume":"10","author":"SC Johnson","year":"2018","unstructured":"Johnson, S. C. et al. The Wisconsin Registry for Alzheimer\u2019s Prevention: a review of findings and current directions. Alzheimers Dement. Diagn. Assess. Dis. Monit. 10, 130\u2013142 (2018).","journal-title":"Alzheimers Dement. Diagn. Assess. Dis. Monit."},{"key":"63545_CR46","doi-asserted-by":"publisher","first-page":"3373","DOI":"10.1093\/brain\/awv267","volume":"138","author":"E Portelius","year":"2015","unstructured":"Portelius, E. et al. Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer\u2019s disease. Brain 138, 3373\u20133385 (2015).","journal-title":"Brain"},{"key":"63545_CR47","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1136\/jnnp.2004.050385","volume":"76","author":"A Nordlund","year":"2005","unstructured":"Nordlund, A. The Goteborg MCI study: mild cognitive impairment is a heterogeneous condition. J. Neurol. Neurosurg. Psychiatry 76, 1485\u20131490 (2005).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"63545_CR48","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1002\/alz.12204","volume":"17","author":"C Van Hulle","year":"2021","unstructured":"Van Hulle, C. et al. An examination of a novel multipanel of CSF biomarkers in the Alzheimer\u2019s disease clinical and pathological continuum. Alzheimers Dement. 17, 431\u2013445 (2021).","journal-title":"Alzheimers Dement."},{"key":"63545_CR49","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1016\/j.jalz.2018.01.010","volume":"14","author":"O Hansson","year":"2018","unstructured":"Hansson, O. et al. CSF biomarkers of Alzheimer\u2019s disease concord with amyloid-\u03b2 PET and predict clinical progression: a study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimers Dement. 14, 1470\u20131481 (2018).","journal-title":"Alzheimers Dement."},{"key":"63545_CR50","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1001\/jamaneurol.2023.5319","volume":"81","author":"NJ Ashton","year":"2024","unstructured":"Ashton, N. J. et al. Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for Alzheimer disease pathology. JAMA Neurol. 81, 255\u2013263 (2024).","journal-title":"JAMA Neurol."},{"key":"63545_CR51","unstructured":"ADNI cohort. https:\/\/adni.loni.usc.edu\/ (2025)."},{"key":"63545_CR52","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.neuroimage.2012.01.021","volume":"62","author":"B Fischl","year":"2012","unstructured":"Fischl, B. FreeSurfer. Neuroimage 62, 774\u2013781 (2012).","journal-title":"Neuroimage"},{"key":"63545_CR53","doi-asserted-by":"publisher","first-page":"5553","DOI":"10.1523\/JNEUROSCI.4409-12.2013","volume":"33","author":"M Wirth","year":"2013","unstructured":"Wirth, M. et al. Alzheimer\u2019s disease neurodegenerative biomarkers are associated with decreased cognitive function but not-amyloid in cognitively normal older individuals. J. Neurosci. 33, 5553\u20135563 (2013).","journal-title":"J. Neurosci."},{"key":"63545_CR54","doi-asserted-by":"publisher","first-page":"4781","DOI":"10.1038\/s41380-022-01716-2","volume":"27","author":"JP Ferrari-Souza","year":"2022","unstructured":"Ferrari-Souza, J. P. et al. Astrocyte biomarker signatures of amyloid-\u03b2 and tau pathologies in Alzheimer\u2019s disease. Mol. Psychiatry 27, 4781\u20134789 (2022).","journal-title":"Mol. Psychiatry"},{"key":"63545_CR55","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13195-018-0402-y","volume":"10","author":"TA Pascoal","year":"2018","unstructured":"Pascoal, T. A. et al. In vivo quantification of neurofibrillary tangles with [18 F]MK-6240. Alzheimers Res. Ther. 10, 74 (2018).","journal-title":"Alzheimers Res. Ther."},{"key":"63545_CR56","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1093\/brain\/awz378","volume":"143","author":"TJ Betthauser","year":"2020","unstructured":"Betthauser, T. J. et al. Amyloid and tau imaging biomarkers explain cognitive decline from late middle-age. Brain 143, 320\u2013335 (2020).","journal-title":"Brain"},{"key":"63545_CR57","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jalz.2016.08.005","volume":"13","author":"CR Jack","year":"2017","unstructured":"Jack, C. R. et al. Defining imaging biomarker cut points for brain aging and Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 13, 205\u2013216 (2017).","journal-title":"Alzheimer\u2019s Dement."},{"key":"63545_CR58","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/j.neurobiolaging.2009.07.002","volume":"32","author":"SM Landau","year":"2011","unstructured":"Landau, S. M. et al. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol. Aging 32, 1207\u20131218 (2011).","journal-title":"Neurobiol. Aging"},{"key":"63545_CR59","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1038\/s41591-023-02443-z","volume":"29","author":"K Horie","year":"2023","unstructured":"Horie, K. et al. CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer\u2019s disease. Nat. Med. 29, 1954\u20131963 (2023).","journal-title":"Nat. Med."},{"key":"63545_CR60","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/0304-4076(81)90071-3","volume":"16","author":"H Akaike","year":"1981","unstructured":"Akaike, H. Likelihood of a model and information criteria. J. Econ. 16, 3\u201314 (1981).","journal-title":"J. Econ."},{"key":"63545_CR61","unstructured":"Burnham K. P. & Anderson D. R. Model Selection and Multimodel Inference (Springer New York, NY, 2002)."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-63545-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-63545-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-63545-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T21:50:36Z","timestamp":1757454636000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-63545-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["63545"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-63545-5","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,29]]},"assertion":[{"value":"31 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.B. has served as a consultant and on advisory boards for AbbVie, AC Immune, ALZPath, AriBio, BioArctic, Biogen, Eisai, Lilly, and Moleac Pte. Ltd, Neurimmune, Novartis, Ono Pharma, Prothena, Roche Diagnostics, and Siemens Healthineers; has served at data monitoring committees for Julius Clinical and Novartis; has given lectures, produced educational materials and participated in educational programs for AC Immune, Biogen, Celdara Medical, Eisai and Roche Diagnostics, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, all unrelated to the work presented in this paper. H.Z. has served on scientific advisory boards and\/or as a consultant for AbbVie, Alector, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Pinteon Therapeutics, Red Abbey Labs, reMYND, Passage Bio, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of BBS. E.R.Z. has served on the scientific advisory board, as a consultant or speaker for Next Innovative Therapeutics (Nintx), Novo Nordisk, Biogen, Lilly, Magdalena Biosciences, and masima. He is also a co-founder and minority shareholder of Masima. P.R.-N. has served on scientific advisory boards and\/or as a consultant for Eisai, Novo Nordisk, and Roche. GE HealthCare holds a license agreement with the University of Pittsburgh based on the PiB PET technology described in this paper. GE HealthCare provided no grant support for this study and had no role in the design or interpretation of results or preparation of this paper. S.C.J. serves on advisory boards for AlzPATH, Lilly, Merck, Alamar, and Enigma Biomedical. B.T.C. is a scientific advisor for Alnyham and has received equipment from Lantheus. T.K.K. has consulted for Quanterix Corporation, SpearBio Inc., Neurogen Biomarking LLC., and Alzheon, and has served on advisory boards for Siemens Healthineers and Neurogen Biomarking LLC., outside the submitted work. He has received in-kind research support from Janssen Research Laboratories, SpearBio Inc., and Alamar Biosciences, as well as meeting travel support from the Alzheimer\u2019s Association and Neurogen Biomarking LLC., outside the submitted work. T.K.K. has received royalties from Bioventix for the transfer of specific antibodies and assays to third-party organizations. He has received honoraria for speaker\/grant review engagements from the NIH, UPENN, UW-Madison, the Cherry Blossom symposium, the HABS-HD\/ADNI4 Health Enhancement Scientific Program, Advent Health Translational Research Institute, Brain Health conference, Barcelona-Pittsburgh conference, the International Neuropsychological Society, the Icahn School of Medicine at Mount Sinai and the Quebec Center for Drug Discovery, Canada, all outside of the submitted work. T.K.K. is an inventor on several patents and provisional patents regarding biofluid biomarker methods, targets, and reagents\/compositions, that may generate income for the institution and\/or self should they be licensed and\/or transferred to another organization. These include WO2020193500A1: Use of a ps396 assay to diagnose tauopathies; US 63\/679,361: Methods to Evaluate Early-Stage Pre-Tangle TAU Aggregates and Treatment of Alzheimer\u2019s Disease Patients; US 63\/672,952: Method for the Quantification of Plasma Amyloid-Beta Biomarkers in Alzheimer\u2019s Disease; US 63\/693,956: Anti-tau Protein Antigen Binding Reagents; and 2450702-2: Detection of oligomeric tau and soluble tau aggregates. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8076"}}